Stride Arcolab Sept qtr PAT seen up 87% at Rs 30.5 cr

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Stride Arcolab September quarter net sales are expected to go up by 27.1% at Rs 547 crore, year-on-year, (YoY) basis.

October 11, 2011 / 17:57 IST

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Stride Arcolab September quarter net sales are expected to go up by 27.1% at Rs 547 crore, year-on-year, (YoY) basis.

The company's net profit (excluding any exceptional gains/losses) is expected to go up 86.6% at Rs 30.5 crore on YoY basis.

first published: Oct 11, 2011 12:44 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Stride Arcolab Sept qtr PAT seen up 87% at Rs 30.5 cr

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Stride Arcolab September quarter net sales are expected to go up by 27.1% at Rs 547 crore, year-on-year, (YoY) basis.

SA10